{
    "clinical_study": {
        "@rank": "31787", 
        "arm_group": {
            "arm_group_label": "Fragmin", 
            "arm_group_type": "Experimental", 
            "description": "Fragmin given according to the flexible dosing regimen outlined in the protocol"
        }, 
        "brief_summary": {
            "textblock": "The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of\n      patients during dialysis."
        }, 
        "brief_title": "Use Of Fragmin In Hemodialysis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Renal Failure", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  chronic renal failure on hemodialysis\n\n        Exclusion Criteria:\n\n          -  significant comorbidities that would prevent a patient from completing the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879618", 
            "org_study_id": "A6301091"
        }, 
        "intervention": {
            "arm_group_label": "Fragmin", 
            "description": "variable dosing regimen", 
            "intervention_name": "Fragmin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dalteparin", 
                "Heparin, Low-Molecular-Weight"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Fragmin", 
            "dalteparin", 
            "hemodialysis", 
            "anticoagulation", 
            "Renal Failure"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6301091&StudyName=Use%20Of%20Fragmin%20In%20Hemodialysis"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 2B7"
                    }, 
                    "name": "University of Alberta Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 2Y9"
                    }, 
                    "name": "Capital District Health Authority-QEII Health Science Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scarborough", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M1P 2V5"
                    }, 
                    "name": "The Scarborough Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2X 3J4"
                    }, 
                    "name": "CHUM - Hopital Saint-Luc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1R 2J6"
                    }, 
                    "name": "CHUQ Research Centre, Hotel-Dieu de Quebec Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Patients With Chronic Renal Insufficiency: The Parrot Study", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clotting in Dialyzer", 
            "measure": "Clotting in Dialyzer", 
            "safety_issue": "No", 
            "time_frame": "0-4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879618"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}